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Liver fibrosis is the result of different types of chronic liver diseases, such as cholestatic liver 
disease and nonalcoholic steatohepatitis, among others.  Fibrosis, if left unchecked, may progress 
to the point of cirrhosis – permanently affecting liver function detrimentally and potentially 
leading to development of hepatocellular carcinoma.  Inflammatory response following tissue 
injury is vital for the initiation of fibrosis; chronic inflammation results in abnormal tissue 
healing and promotes a pro-fibrogenic response. 
Activins are cytokines that have been identified as members of the TGFβ superfamily of growth 
and differentiation factors.  Activin A and B, in particular, have been identified as having roles in 
the pathophysiology of liver disease, but have not been investigated thoroughly.  We treated 
mice with concanavalin A, a potent T-cell mitogen with liver specificity when administered 
intravenously, and characterized the resulting response to liver injury and how activin A and B 
are modulated during this acute inflammatory phase.  We showed that activin B is highly 
increased in circulation following inflammation, as well as locally in the liver as well as the 
spleen.  We then neutralized activin A and B via neutralizing antibodies in our concanavalin A-
induced liver injury model to determine if inhibition of these ligands may confer protective 
effects during the acute inflammatory response in liver.  Neutralization of either activin A or 
activin B protected hepatocytes, improved liver function, and significantly reduced circulating 
cytokines following concanavalin A administration.  Finally, we determined whether inhibition 
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of activin A or B might prevent or reverse the development of liver fibrosis after disease has 
been established.  We induced liver fibrosis in mice via the hepatotoxin carbon tetrachloride, and 
then treated with neutralizing antibodies while still maintaining carbon tetrachloride 
administration.  Neutralization of activin A and B markedly reduced liver fibrosis, protected 
hepatocytes, and improved liver function.  Our findings implicate both activin A and B as major 
players in the acute inflammatory response to liver injury, as well as during chronic injury and 
fibrogenesis, and demonstrate the therapeutic potential of targeting these ligands for the 
treatment of fibrosis in chronic liver diseases. 
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CHAPTER 1. LITERATURE REVIEW 
 
1.1 Liver injury and fibrosis 
Liver fibrosis is the product of chronic liver damage, in addition to excess accumulation of 
extracellular matrix (ECM) proteins in the liver, and is characteristic of most types of chronic 
liver diseases, such as cholestatic liver disease and nonalcoholic steatohepatitis (NASH) 1,2.  In 
acute liver failure, generally a robust and self-limiting fibrotic and regenerative response occurs 
3.  This fibrotic response becomes an issue, however, when dysregulated and excessive scarring 
occurs in response to persistent injury and alters tissue function 4.  Eventually, if left unchecked, 
liver fibrosis will progress to the point of liver cirrhosis where damage to the liver is generally 
regarded as irreversible, and may eventually result in hepatocellular carcinoma (HCC). 
Insult or damage to epithelial cells in the liver (either hepatocytes or cholangiocytes) results in 
the release of inflammatory mediators, leading to the stimulation and activation of hepatic 
stellate cells (HSCs) which transdifferentiate to become myofibroblast-like cells, characterized 
by an excessive release of ECM proteins and release of pro-inflammatory and pro-fibrogenic 
factors including TGFβ 4.  Following damage leukocytes are recruited to the site of injury to 
phagocytize apoptotic or dead cells and amplify inflammatory response by secreting pro-
inflammatory cytokines (including TGFβ), as well as by recruiting additional T-cells 4.  Pro-
inflammatory mediators, growth factors, and cytokines (including PDGF, CTGF, TGFβ, and IL-
13) from cellular damage and stimulated immune cells activate mesenchymal precursor cells to 
transdifferentiate to myofibroblasts as well 4,5. However, mechanisms driving the initiation and 
progression of liver fibrosis remain elusive. 
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Figure 1-1: Schematic of liver fibrogenesis. Ismail, Reversal of hepatic fibrosis: 
pathophysiological basis of antifibrotic therapies November 2013. 
 
1.2 Lymphocytes in Immune Responses 
Lymphocytes are white blood cells that vary in function and include T, B, and natural killer (NK) 
cells; T and B cells are the effectors of adaptive immunity, and NK cells lack recombined 
antigen receptors and are innate immune lymphocytes 6.  Lymphocytes are essential in the 
immune response to foreign antigen and through continual recirculation between specific sites 
facilitate both continual immune surveillance, and recognition and response to antigen when it 
enters the body 7.  During development, lymphocyte lineage and specificity are determined 
through generation of either T-cell receptor (TCR) for T-cells or B-cell receptor (BCR) for B-
cells.  NK cells are unique in the fact that they do not express either TCR or BCR, and do not 
require antibody or major histocompatibility complex (MHC) in order to activate.  MHC is a 
molecule expressed on the surface of all nucleated cells (and platelets) of jawed vertebrates, and 
is required for priming of naïve T-cells.  When T cells encounter MHC bound with antigen on 
antigen presenting cells (APCs) such as dendritic cells (DC) or macrophages, TCR signals result 
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in changes in adhesion molecules to promote continued binding of the two cells which allows for 
costimulatory signaling though CD28 (on the T-cell) and B7-1/2 (also known as CD80/86) (on 
the APC) in CD8+ cells.  In CD4+ cells, the costimulatory signaling is through CD40L (on the 
T-cell) and CD40 (on the APC).  Priming of naïve CD8+ T-cells (which bind MHCI expressed 
on all nucleated cells and platelets) results in cytotoxic T-cells (CTL), which can directly kill 
pathogen-infected cells through the release of perforin, granzymes, and granulysin - which lead 
to a cascade of events that trigger apoptosis in the target cell.  Primed CD4+ cells (which bind 
MHCII expressed on professional APCs such as B-cells, dendritic cells, and mononuclear 
phagocytes) develop into a diverse array of effector cell types that express specific master 
transcription factors depending on cytokines generated from innate cells during the priming 
process as well as the strength of the antigenic stimulation 8.   
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Figure 1-2: CD4+ and CD8+ T-cell signaling. Thaiss, Chemokines: a new dendritic cell signal 
for T cell activation August 2011. 
 
1.3 Immune cells in liver injury and fibrosis 
Regarding fibrosis in the liver, many of the cells involved in the innate immune response may 
only have a minimal effect on tissue fibrosis 9.  In fact, NK cells have been shown to actively 
suppress fibrosis by termination of activated myofibroblasts through TRAIL dependent 
mechanisms 10.  Macrophages, however, are responsible for both the progression and resolution 
of fibrosis in the liver.  Macrophages contribute to the initiation of fibrogenesis through 
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production of TGFβ1 and insulin-like growth factor, which promotes fibroblast expression to 
start matrix remodeling 11.  Additionally, macrophages have been shown to produce IL-6 and 
TGFβ, which leads to maintenance of proliferation and differentiation in fibroblasts 12.   
Macrophages follow two distinct patterns of activation and polarization following stimulation.  
Following stimulation with Toll-like receptor (TLR) ligands, IFN-γ (produced by Th1 cells and 
NK cells) and TNF (produced by APC cells) macrophages undergo classical activation 
(becoming M1 macrophages) 13.  These macrophages are characterized by secretion of multiple 
pro-inflammatory cytokines (IFN-γ, IL-1, IL-6, IL-12, IL-23 and TNFα) and are associated with 
Th1 lymphocyte response and cell-mediated immunity 9.  Macrophages may also undergo 
alternative activation, becoming M2 macrophages.  This activation profile is a Th2 polarized 
response characterized by STAT-6 signaling, secretion of IL-4 and IL-13, and upregulation of 
endocytic lectin receptors 9.  M2 macrophages are generally associated with resolution of 
inflammation (through production of immunosuppressive IL-10) or wound healing (through 
production of IL-4 and upregulation of arginase, the enzyme associated with production of 
polyamides and collagen) 14. 
The human liver contains a significant number of resident lymphocytes (~1010 cells), which are 
comprised of both adaptive lymphocytes (B cells, CD4+ cells, and CD8+ cells) as well as innate 
lymphocytes (NK and NKT cells) 15.  Depletion of either T-cells or B-cells have been shown to 
have protective effects from fibrosis in the liver 16,17.  Additionally, RAG2-/- mice deficient in 
both T and B-cells show resistance to fibrosis in acute and chronic models of liver injury 17.  The 
interaction of T helper cells during acute and chronic inflammation drives the polarity of the 
response, and different expression profiles result from the cytokines produced by either Th1 or 
Th2 cells.  Generally, cytokines produced by Th1 cells (such as IFN-γ, IL-2, and TNFC) are 
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associated with an intense cellular response through cell-mediated immunity and phagocyte-
dependent inflammation 18.  Th2 cytokines, on the other hand, increase the expression of several 
pro-fibrogenesis genes including pro-collagen I and III, MMP2, MMP9 and TIMPs 12.  Blocking 
receptor for IL-13 signaling, a pro-fibrosis cytokine produced by Th2 cells 19, has been shown to 
reduce liver fibrosis 20.  Additionally, using targeted mutations to disrupt IL-4 and its receptor, as 
well as STAT6 also attenuate liver fibrosis in mice 21.  Regarding cytotoxic T-cells - transfer of 
CD8+ cells, but not CD4+ cells, from mice with liver fibrosis induced by CCl4 treatment into 
immune compromised SCID mice results in significant liver injury 16.  In the context of fibrosis 
in the liver, CD4+ cells are responsible for local production of cytokines that promote 
fibrogenesis by affecting macrophages and fibroblasts, while CD8+ cells promote local tissue 
injury by releasing pro-inflammatory cytokines that may indirectly lead to fibrosis 9.  
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Figure 1-3: Interactions of the innate and adaptive immune systems in liver fibrosis. Holt, 
Immune interactions in hepatic fibrosis. or “Leucocyte-stromal interactions in hepatic 
fibrosis” November 2018. 
 
1.4 Activin A and B in liver injury and fibrosis 
Activins are a group of cytokines classified under the TGFβ superfamily of growth and 
differentiation factors 22, like TGFβ, are formed via the covalent dimerization of two subunits 23.  
In humans and other mammals, four subunits of activin have been identified: beta A, beta B, beta 
C and beta E.  Of all of these subunits – A, B, and C have been found in humans, and A, B, C, 
and E in mouse.  Activin A is the homodimer of two beta A subunits, and activin B is the 
homodimer of two beta B subunits.  Activin has both a type I and type II receptor which both 
contain a short extracellular domain that binds ligand, and a larger intracellular serine/threonine 
kinase domain 24. The type II receptor (ActR-II or ActR-IIB) is constitutively active, and will 
dimerize and bind activin A and B first 24.  Afterwards, the bound type II receptors will recruit a 
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type I receptor (ActR-IA/B) each and activate them via phosphorylation of the membrane-
proximal glycine- and serine-rich sequence (GS) region 25.  When they bind to the same type II 
receptor, activins A and B recruit ALK7 (ACVR1C) as the type I receptor 26.  Following ligand 
binding, receptors are internalized 27; the SMAD anchor for receptor activation (SARA) is a zinc 
double finger FYVE domain containing protein present in the early endosome which is 
internalized along with the hetero-tetrameric receptor complex via clathrin-mediated endocytosis 
28.  SARA then will recruit a receptor-regulated SMAD (R-SMAD), orienting the R-SMAD so 
that the serine residue on its C-terminus can bind the catalytic L45 region of the Type I receptor 
29.  The type I receptor will then phosphorylate this serine residue of the R-SMAD, inducing a 
conformational change which allows dissociation of the R-SMAD from the receptor complex 
and SARA 30.  Activins have been shown to signal through the R-SMADS SMAD 2 and SMAD 
3 31. The dissociated, phosphorylated R-SMAD then binds the common mediator Smad 4 and 
this complex translocates to the nucleus to regulate gene expression 32. 
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Figure 1-4: Activin receptor signaling. Werner, Roles of activin in tissue repair, fibrosis, and 
inflammatory disease February 2006. 
 
Activin A has a wide tissue distribution and is produced by numerous cells including 
macrophages, Th2 cells, and hepatocytes 32–34.  Activin A is an important mediator of liver 
pathophysiology, through proliferation of hepatocytes, activation of HSCs, secretion of liver 
extracellular matrix, and the formation and development of liver injury 35.  Activin A expression 
is significantly elevated in CCl4-induced chronic liver injury in mice, marking it as a potential 
regulator of liver fibrosis development 36.  Additionally, activin A protein in serum as well as 
liver is significantly increased in a mouse model of immune hepatitis and fibrosis, and 
knockdown of activin A type 2 receptor in this model resulted in significant reductions in ALT 
and AST (liver enzyme markers of damage), hydroxyproline in liver, and hepatic fibrosis as 
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measured by Masson trichrome staining 37.  In humans, activin A levels in serum have been 
shown to be significantly elevated in individuals with non-alcoholic fatty liver disease (NAFLD).  
In patients with non-alcoholic steatohepatitis (NASH) high levels of activin A are significantly 
correlated with the degree of hepatic fibrosis 38.  Taken together, these lines of evidence 
implicate a functional role for activin A in liver homeostasis and disease, which, however, has 
not been intensively studied.   
The function of activin B in the liver is poorly understood 39.  Expression of beta B subunit of 
activin is low in rodent liver 40, but is detectable by immunohistochemistry at low levels in 
hepatocytes of normal rat livers and in connective tissue septa in fibrotic livers 41.  In humans, 
however, beta A and beta B transcripts are expressed at similar levels in liver 42.  Expression of 
activin beta B mRNA has been shown to be highly upregulated in stellate cells of rat livers 
following CCL4 administration 
43 and following exposure to peroxisome proliferator di-n-butyl 
phthalate 44.  Additionally, in a model of lipopolysaccharide (LPS)-induced liver inflammation in 
mice βB subunit expression levels are significantly increased, but not inhibin α or βA subunit 45. 
These data taken together suggest a role for activin B in the pathology of liver inflammation and 
fibrosis.   
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1 Animal care and use 
All mouse studies were performed with the approval of Eli Lilly and Company’s Institutional 
Animal Care and Use Committee in accordance with the National Institute of Health Guide for 
the Care and Use of Laboratory Animals.  For concanavalin A immune-mediated hepatitis 
studies, male Balb/c mice were used (Envigo, Indianapolis, IN) at 12 weeks of age.  For carbon 
tetrachloride (CCl4) induced liver fibrosis, female C57BL/6 mice were used (Envigo, 
Indianapolis, IN) at 12 weeks of age.  Animals were allowed to acclimate for a minimum of 72 
hours in a climate controlled room (22±2°C) on a 12-hour light-dark cycle (with lights on at 
6:00AM) with ad lib access to water and normal chow (TD2014, Teklad, Madison, WI).  Prior to 
study start, animals were randomized according to body weight. 
2.2 Concanavalin A immune-mediated hepatitis 
Acute immune-mediated hepatitis was induced by a single intravenous (IV) administration of 
concanavalin A (MP Biomedical, Solon, OH) dissolved in phosphate-buffered saline (200 μL per 
animal).  For the initial dose-response characterization study, concanavalin A was administered 
at 10 mg/kg, 15 mg/kg, 20 mg/kg, or 25 mg/kg.  For the second study, mouse IgG1 isotype 
control (50 mg/kg), activin A (10 mg/kg) or activin B (50 mg/kg) neutralizing antibodies (Eli 
Lilly, Indianapolis, IN) in phosphate-buffered saline were administered subcutaneously (SC) at 
16 hours prior to concanavalin A injection, which was administered at 15 mg/kg.  12 hours 
following concanavalin A administration, mice were sacrificed by CO2 asphyxiation and blood 
collected via cardiac puncture and serum separated using MiniCollect Z serum separating tubes 
(Greiner Bio-one, Kremünster, Australia) .  Following blood collection, a secondary method of 
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euthanasia was performed (cervical dislocation) and liver, gastrocnemius, and spleen were 
excised and either snap-frozen in liquid nitrogen or fixed in 10% neutral-buffered formalin for 
histological analysis.  Serum and frozen tissues were stored at -80 °C until analyzed.   
2.3 CCl4-induced liver fibrosis 
Hepatic fibrosis was induced via intraperitoneal (IP) injections of CCl4 (1 mL/kg) diluted 1:10 in 
corn oil twice weekly for 6 weeks.  Control animals were given only corn oil following the same 
dosing regimen as CCl4-treated mice.  After 6 weeks of CCl4 administration, mouse IgG1 isotype 
control (60 mg/kg), activin A antibody (10 mg/kg), activin B antibody (50 mg/kg), the 
combination of both neutralizing antibodies, or soluble activin receptor type IIB (Eli Lilly, 
Indianapolis, IN) were administered once weekly for 4 weeks.  During this 4 week period, CCl4 
was still administered twice weekly at 1 ml/kg.  Following 4 weeks of treatment, mice were 
sacrificed by CO2 asphyxiation and blood collected via cardiac puncture and processed for 
serum.  Following blood collection, a secondary method of euthanasia was performed (cervical 
dislocation) and liver, gastrocnemius, and spleen were excised and fixed in 10% neutral-buffered 
formalin for histological analysis.  Serum was stored at -80 °C until analyzed. 
2.4 Body composition (quantitative NMR) 
 
In animals treated with CCl4, quantitative nuclear magnetic resonance (qNMR) imaging was 
performed at the beginning of the study before CCl4 administration and after 6 weeks of CCl4 
administration.  During the antibody treatment phase, qNMR was performed weekly and prior to 
study termination.  Lean body mass, fat mass, and free water content were measured (qNMR; 
Echo Medical systems, Houston, TX). 
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2.5 Biochemical assays 
Serum samples were analyzed for aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), glucose, bile acids, total cholesterol, and total bilirubin levels with a Hitachi Modular 
Analyzer (Roche Diagnostics, Indianapolis, IN).  For concanavalin A studies, serum activin A 
and activin B protein contents were measured via ELISA according to the manufacturer’s 
protocols (activin A ELISA kit, Sigma, St. Louis, MO; activin B ELISA kit, Ansh labs, Webster, 
TX).  Additionally, for the concanavalin A dose response study, activin A and activin B protein 
levels were measured in liver and spleen.  Tissue lysates were processed using approximately 
100 mg of tissue with 1mL of lysis buffer (Cell Signaling Technologies, Dancers, MA), with 
protease inhibitor added (protease inhibitor tablets EDTA-free; Pierce Biotechnology, Rockford, 
IL).  Total protein concentrations were measured via Bradford assay (Coomassie plus protein 
assay; Pierce Biotechnology, Rockford, IL) and protein content between tissue samples 
normalized before performing ELISAs.  For the concanavalin A antibody study, serum samples 
were measured for cytokine levels using V-PLEX Plus Proinflammatory Panel 1 kit (Meso Scale 
Discovery, Rockville, MD) according to the manufacturer’s protocol. 
2.6 Histology and immunohistochemistry  
For the CCl4 study, fixed liver samples were processed, paraffin-embedded, and subjected to a 
standard procedure of immunohistochemistry. Primary antibodies against F4/80 (eBioscience, 
San Diego, CA), MPO (R&D System, Minneapolis, MN), and Ki67 (Abcam, Cambridge, MA) 
were used. The liver sections were subjected to Masson's trichrome staining (Abcam, 
Cambridge, MA) as well.  Images were acquired using digital slide scanning (ScanScope XT, 
Aperio, Vista, CA) and quantification of stained areas performed using ImageJ (National 
Institutes of Health, NIH, USA). 
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2.7 Quantitative real-time PCR 
mRNA in liver and spleen from the concanavalin A dose response study was isolated by adding 
1ml of TRIzol reagent (Ambion, Carlsbad, CA) to tissue samples in lysing matrix D FastPrep 
tubes (MP Biomedicals, Solon, OH); samples were then homogenized (Fast-Prep96, MP 
Biomedicals, Solon, OH).  The manufacturer’s protocol for RNA isolation with TRIzol was 
followed until phase separation, then aqueous phase was removed and RNA isolated and purified 
using PureLink Pro 96 purification kit (Invitrogen, Carlsbad, CA).  RNA concentration and 
purity was assessed by measuring sample absorbance at 260/280 nm via Nanodrop 
(ThermoFisher Scientific, Wilmington, DE).  2 μg of RNA was reverse-transcribed to cDNA 
using a high capacity cDNA reverse-transcription kit (Applied Biosystems, Forster City, CA) in 
a 20ul reaction.  cDNA was combined with TaqMan Universal Fast Master Mix (Applied 
Biosystems, Forster City, CA) and TaqMan primer probes (Applied Biosystems, Forster City, 
CA), and qPCR analysis performed via QuantStudio 7 Flex system (Applied Biosystems, 
Carlsbad, CA).  Threshold values were generated for Inhibin A (Inhba, Mm00434339_m1) and 
Inhibin B (Inhbb, Mm03023992_m1) in both liver and spleen, and data reported as 2–∆∆Ct relative 
to control.  For liver, the housekeeping gene used was Hprt1 (Hprt, Mm00446968_m1).  For 
spleen, the housekeeping gene used was β-actin (Actb, Mm02619580_g1). 
2.8 Data analysis 
All data expressed as mean ±SEM. Statistical analysis was performed using GraphPad Prism 
version 7.  Statistical significance (p-value ≤0.05) was analyzed by one-way ANOVA. 
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CHAPTER 3. RESULTS 
 
3.1 Characterization of concanavalin A immune-mediated hepatitis  
We evaluated an in vivo model of acute hepatitis induced by intravenous concanavalin A 
administration in mice to explore the relationship between immune system activation during 
acute inflammation and how activin A and B may be involved.  Animals were separated into five 
groups (n=6) and administered varying doses of concanavalin A (Table 3-1): 
Table 3-1 Groups in concanavalin A characterization study 
Group Number Stimulation 
1 PBS (200 μL, IV) 
2 ConA (10 mg/kg, IV) 
3 ConA (15 mg/kg, IV) 
4 ConA (20 mg/kg, IV) 
5 ConA (25 mg/kg, IV) 
 
Concanavalin A is a plant lectin extracted from the jack-bean (Canavalia ensiformis) and when 
delivered intravenously is a liver-specific T-cell selective mitogen, crosslinking surface 
glycoprotein located on liver sinusoidal endothelial cells to T-cell receptors on T-cells and 
Kupffer cells, activating them 46.  In this way the concanavalin A model differentiates itself from 
other models as insult to liver is highly specific and mediated solely through lymphocyte 
activation and immune-mediated damage, versus through primary damage to hepatic 
parenchymal tissue followed by secondary immune-mediated damage (CCL4 model), or through 
less tissue-specific innate and adaptive immune responses (LPS mediated) 46.  We anticipated 
that following concanavalin A immune-mediated damage to hepatocytes would be reflected 
through increases in serum clinical markers for liver damage (aspartate aminotransferase (AST), 
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alanine aminotransferase (ALT), total bilirubin, etc.).  As response to concanavalin A and 
cytokine profile will vary based on time from administration, we focused on evaluating the time 
at which maximum damage to liver is achieved based on increases to clinical markers, which is 
roughly 12 hours after treatment 43.   
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Figure 3-1 Response of ALT and AST to intravenous concanavalin A administration.  Lean 
male Balb/c mice were administered a single dose of concanavalin A intravenously.  Serum levels of 
ALT (A) and AST (B) were measured from serum collected 12 hours post-dose.  Data are expressed 
as mean ± S.E.M. (n=6 mice/group). Significance is indicated **P ≤ 0.01, treated group versus 
vehicle control group (Dunnett’s one-way ANOVA).   
 
Concanavalin A treatment showed increases in serum ALT and AST starting at 15 mg/kg, 
reaching highly significant differences compared to vehicle control at 25 mg/kg.  Increasing 
dosage threshold from 20 mg/kg to 25 mg/kg resulted in a substantial increase in both ALT and 
AST in serum.  We also measured total bilirubin and bile acids in serum, which followed the 
same trend that with increasing dosage of concanavalin A, clinical parameters increased. 
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Figure 3-2 Response of bilirubin and bile acids to intravenous concanavalin A 
administration. Lean male Balb/c mice were administered a single dose of concanavalin A 
intravenously.  Serum levels of bilirubin (A) and bile acids (B) were measured from serum collected 
12 hours post-dose.  Data are expressed as mean ± S.E.M. (n=6 mice/group).  
 
Additionally, we also evaluated serum glucose and total cholesterol levels following concanavalin A 
treatment as liver gluconeogenesis and cholesterol homeostasis and metabolism are negatively 
impacted following liver injury.  We found that with increasing dosage of concanavalin A, blood 
glucose levels were significantly decreased starting at 15mg/kg and steadily decreased throughout 
increasing dosage.  There were no significant effects on circulating cholesterol in serum. 
31 
 
 
V
e
h
i c
l e
 (
P
B
S
,  
2
0
0
u
l  
I V
)
C
o
n
A
 1
0
m
g
/ k
g
C
o
n
A
 1
5
m
g
/ k
g
C
o
n
A
 2
0
m
g
/ k
g
C
o
n
A
 2
5
m
g
/ k
g
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
G
lu
c
o
s
e
 (
m
g
/d
L
)
* * * *
V
e
h
i c
l e
 (
P
B
S
,  
2
0
0
u
l  
I V
)
C
o
n
A
 1
0
m
g
/ k
g
C
o
n
A
 1
5
m
g
/ k
g
C
o
n
A
 2
0
m
g
/ k
g
C
o
n
A
 2
5
m
g
/ k
g
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
T
o
t
a
l 
C
h
o
le
s
t
e
r
o
l 
(
m
g
/d
l)
A B
 
Figure 3-3 Response of glucose and cholesterol to intravenous concanavalin A 
administration. Lean male Balb/c mice were administered a single dose of concanavalin A 
intravenously.  Serum levels of glucose (A) and cholesterol (B) were measured from serum collected 
12 hours post-dose.  Data are expressed as mean ± S.E.M. (n=6 mice/group).  Significance is 
indicated *P ≤ 0.05, **P ≤ 0.01, treated group versus vehicle control group (Dunnett’s one-way 
ANOVA).    
 
We demonstrated that in our hands, concanavalin A administered intravenously acts as a potent 
immune cell mitogen in the liver, and damages hepatocytes dose-dependently through 
lymphocyte and macrophage-mediated mechanisms as measured by relevant clinical markers of 
liver function.  However, how systemic and tissue-specific activin A and B levels are affected 
following concanavalin A administration has not been well characterized.  To date, only activin 
A has been shown to be slightly increased following chronic (6 week) weekly IV administration 
of low dosage of concanavalin A (8 mg/kg) 37, which according to our data would be considered 
a sub-optimal dose to elicit relevant increases in clinical parameters of liver injury.  Additionally, 
it has been demonstrated that concanavalin A is not suitable for development of chronic liver 
injury or disease, as mice become immunologically tolerant against concanavalin A-induced 
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liver inflammation after successful initial resolution (within roughly 8 days) 47.  Therefore, we 
measured circulating levels of both activin A and B following acute concanavalin A 
administration to ascertain whether systemic activin production is modulated in this disease 
model.  What we found was that 12 hours following administration, circulating activin A levels 
were increased (although not significantly) at 10, 15, and 20 mg/kg dosages of concanavalin A.  
However, to our surprise, activin B levels showed a massive significant increase at every dosage 
of concanavalin A administered. 
V
e
h
i c
l e
 (
P
B
S
,  
2
0
0
u
l  
I V
)
C
o
n
A
 1
0
m
g
/ k
g
C
o
n
A
 1
5
m
g
/ k
g
C
o
n
A
 2
0
m
g
/ k
g
C
o
n
A
 2
5
m
g
/ k
g
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
1 0 0 0 0
1 1 0 0 0
1 2 0 0 0
1 3 0 0 0
1 4 0 0 0
1 5 0 0 0
S
e
r
u
m
 
A
c
t
iv
i
n
 B
 (
p
g
/m
L
)
* * * *
* * * *
* * * *
* * * *
A B
V
e
h
i c
l e
 (
P
B
S
,  
2
0
0
u
l  
I V
)
C
o
n
A
 1
0
m
g
/ k
g
C
o
n
A
 1
5
m
g
/ k
g
C
o
n
A
 2
0
m
g
/ k
g
C
o
n
A
 2
5
m
g
/ k
g
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
S
e
r
u
m
 
A
c
t
iv
i
n
 A
 (
p
g
/m
L
)
 
Figure 3-4 Systemic activin A and B levels following intravenous concanavalin A 
administration. Lean male Balb/c mice were administered a single dose of concanavalin A 
intravenously.  Serum levels of activin A (A) and activin B (B) were measured by ELISA from 
serum collected 12 hours post-dose.  Data are expressed as mean ± S.E.M. (n=6 mice/group).  
Significance is indicated ****P ≤ 0.0001, treated group versus vehicle control group (Dunnett’s one-
way ANOVA).    
 
Of particular interest regarding levels of activin B in circulation following concanavalin A 
administration is the fact that there is no correlation whatsoever to clinical parameters of liver 
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injury.  Each dose of concanavalin A we evaluated saturated in terms of magnitude of increase in 
circulating activin B compared to control.  Even at 10 mg/kg, where we saw no obvious 
increases to any markers of liver injury, increase in circulating activin B is equivalent to that 
seen in the 25 mg/kg group, where liver damage (as reflected by ALT and AST levels) is very 
appreciable.  It is quite apparent that modulation of activin B plays an important role in the 
pathophysiology of immune-mediated liver injury, as reflected by the robust increase in 
circulating activin B in our study; cellular sources of activin B have not definitively been 
identified, however.  Following stimulation with lipopolysaccharide, immunolocalization of 
inhibin βB has been performed via immunohistochemistry in mouse livers, which suggests 
vascular endothelial cells and Kupffer cells as potential sources 45, although there may be 
other sources of activin B production as well.  We examined expression levels of inhibin A 
and B in both liver and spleen in this model to further identify where transcription of these 
genes may be modulated following immune-mediated injury to the liver. 
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Figure 3-5 Inhibin A and B expression in the liver following intravenous concanavalin A 
administration. Lean male Balb/c mice were administered a single dose of concanavalin A 
intravenously.  Transcript levels of inhibin A (A) and inhibin B (B) were quantified via qPCR using 
the 2–∆∆Ct method from snap-frozen liver collected 12 hours post-dose, using hprt as the 
housekeeping gene.  Data are expressed as mean ± S.E.M. (n=6 mice/group).  Significance is 
indicated *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005, treated group versus vehicle control group (Dunnett’s 
one-way ANOVA).    
 
Following administration of concanavalin A, expression of inhibin A in the liver is significantly 
downregulated at 12 hours post dose for all dosages.  In a model of acute inflammation induced 
by LPS administration, peak production of circulating activin A is achieved very quickly, within 
one hour of injection, and only remains slightly elevated compared to baseline from 3 hours up 
until 12 hours post administration 48.  This downregulation of activin A expression and only 
slight elevation in circulating ligand 12 hours post-dose may be in response to rapid, transient 
elevation of activin A following inflammatory response.  In contrast, inhibin B transcription is 
highly upregulated (approximately 50-fold) 12 hours following concanavalin a administration, 
mimicking the massive increase seen in circulating ligand.  It seems likely that due to the large 
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increase in expression of inhibin B, some population of resident liver cells or infiltrating immune 
cells are likely responsible for the increased production of circulating ligand.   
V
e
h
i c
l e
 (
P
B
S
,  
2
0
0
u
l  
I V
)
C
o
n
A
 1
0
m
g
/ k
g
C
o
n
A
 1
5
m
g
/ k
g
C
o
n
A
 2
0
m
g
/ k
g
C
o
n
A
 2
5
m
g
/ k
g
0
5
1 0
1 5
2 0
2 5
I n h i b i n  A  S p l e e n
F
o
ld
 C
h
a
n
g
e
 N
o
r
m
a
li
z
e
d
 t
o
 V
e
h
ic
le
*
V
e
h
i c
l e
 (
P
B
S
,  
2
0
0
u
l  
I V
)
C
o
n
A
 1
0
m
g
/ k
g
C
o
n
A
 1
5
m
g
/ k
g
C
o
n
A
 2
0
m
g
/ k
g
C
o
n
A
 2
5
m
g
/ k
g
0
5
1 0
1 5
2 0
2 5
I n h i b i n  B  S p l e e n
F
o
ld
 C
h
a
n
g
e
 N
o
r
m
a
li
z
e
d
 t
o
 V
e
h
ic
le
*
*
*
BA
 
Figure 3-6 Inhibin A and B expression in the spleen following intravenous concanavalin A 
administration. Lean male Balb/c mice were administered a single dose of concanavalin A 
intravenously.  Transcript levels of inhibin A (A) and inhibin B (B) were quantified via qPCR using 
the 2–∆∆Ct method from snap-frozen spleen collected 12 hours post-dose, using beta-actin as the 
housekeeping gene.  Data are expressed as mean ± S.E.M. (n=6 mice/group).  Significance is 
indicated *P ≤ 0.05, treated group versus vehicle control group (Dunnett’s one-way ANOVA) 
 
In the spleen, inhibin A expression is slightly upregulated starting at 15 mg/kg and dose-
dependently increases, reaching significance at 25 mg/kg.  This is not a surprising finding, given 
that stimulated CD4+ T-cells have been shown to produce activin A in vitro 33.  Regarding 
inhibin B, expression is increased to a larger extent than inhibin A, and is significantly increased 
from the 15 m/kg dosage on.  This increase in transcription of inhibin B may be indicative of 
splenocytes an alternative source of activin B ligand in this model, be it activated T-cells, 
macrophages, or some other cell type.  We also examined tissue-specific protein levels for 
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activin A and B in liver to corroborate whether increased expression led to increased local 
production of ligand. 
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Figure 3-7 Liver activin A and B levels following intravenous concanavalin A 
administration. Lean male Balb/c mice were administered a single dose of concanavalin A 
intravenously.  Tissue-specific levels of activin A (A) and activin B (B) were measured by ELISA 
from liver lysates collected 12 hours post-dose.  Data are expressed as mean ± S.E.M. (n=6 
mice/group).  Significance is indicated *P ≤ 0.05, **P ≤ 0.01, treated group versus vehicle control 
group (Dunnett’s one-way ANOVA). 
 
In the liver, there are no significant changes to local production of activin A 12 hours following 
concanavalin A administration, consistent with serum levels and liver transcript data.  Activin B 
production is dose-dependently increased in the liver following concanavalin A administration, 
reaching statistically significant difference at 15 mg/kg.   
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Figure 3-8 Spleen activin A and B levels following intravenous concanavalin A 
administration. Lean male Balb/c mice were administered a single dose of concanavalin A 
intravenously.  Tissue-specific levels of activin A (A) and activin B (B) were measured by ELISA 
from spleen lysates collected 12 hours post-dose.  Data are expressed as mean ± S.E.M. (n=6 
mice/group).  Significance is indicated **P ≤ 0.01, ***P ≤ 0.005, treated group versus vehicle 
control group (Dunnett’s one-way ANOVA). 
 
In the spleen, there are no significant changes to local production of activin A 12 hours following 
concanavalin A administration, even though we saw significant upregulation of inhibin A.  
Regarding activin B, there is a dose-dependent decrease in local ligand production, with the lowest 
dose of concanavalin A showing significant increase in ligand production and gradual reduction with 
increasing dose until reaching the highest dose, where activin B levels are similar to vehicle control.  
Following activation and clearance of antigen, activated T-cells need to be cleared in order to ensure 
tolerability in the periphery, maintain lymphocyte homeostasis and prevent autoimmunity 49.  
Activation-induced cell death (AICD) is one mechanism though which apoptosis is induced in 
activated T-cells through re-stimulation of the T-cell receptor following initial activation and 
expansion 50.  It is likely in the higher dosage groups that re-stimulation of T-cells may be occurring 
during the contraction phase following initial stimulation, where activated T-cells are highly sensitive 
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to AICD 51, simply due to the fact that antigen may still be present and not fully cleared.  This may 
explain why with increasing stimulation, we see decreasing protein production, as activated T-cells 
potentially responsible for production of activin B may be re-stimulated by concanavalin A not 
already cleared in the higher dosage groups, inducing cell death and leading to lower local 
production of ligand. 
3.2 Antibody neutralization of activin A and B in concanavalin A immune-mediated 
hepatitis 
We sufficiently characterized both activin A and B in response to acute liver injury induced by 
immune-mediated hepatitis though concanavalin A administration.  We next sought to determine 
whether neutralization of either activin A or B might confer beneficial effects in this particular 
model.  Animals were separated into five groups (n=8) and administered stimulation or 
treatments listed below (Table 3-2): 
Table 3-2 Groups in concanavalin A activin A and B neutralization study 
Group Number Treatment Stimulation 
1 PBS (200 μL, SC) PBS (200 μL, IV) 
2 mIgG1 (50 mg/kg, SC) ConA (15 mg/kg, IV) 
3 
Anti-Activin A (10 
mg/kg, SC) 
ConA (15 mg/kg, IV) 
4 
Anti-Activin B (50 
mg/kg, SC) 
ConA (15 mg/kg, IV) 
 
Dosage of activin A antibody was determined from a previous study showing efficacy of muscular 
degeneration in a muscle injury model run previously 52.  Activin B antibody was shown to have an 
IC50 that was 5-fold higher than activin A antibody by Smad2/3 binding element promoter 
luciferase assay (data not shown), so we utilized a 5x dose compared to activin A antibody.  We 
utilized a standard dose of 15 mg/kg for concanavalin A, as this was the lowest dosage to have 
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any sort of significant impact on clinical parameters of liver function, giving us the best chance 
to see effect following antibody treatment.    Antibodies were dosed 16 hours prior to 
concanavalin A administration, and animals were sacrificed 12 hours following concanavalin A 
administration. 
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Figure 3-9 Tissue wet weights following activin antibody treatment and intravenous 
concanavalin A administration. Lean male Balb/c mice were administered antibody treatment 
listed and a single dose of concanavalin A intravenously 16 hours later.  Wet tissue weights of 
gastrocnemius (A), spleen (B), and liver (C) were measured 12 hours post-dose.  Data are expressed 
as mean ± S.E.M. (n=8 mice/group).  Significance is indicated **P ≤ 0.01, ****P ≤ 0.001, treated 
group versus IgG control group (Dunnett’s one-way ANOVA). 
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Concanavalin A administration significantly induces hepatomegaly and splenomegaly 12 hours 
following administration; neither activin A nor B antibody treatment was effective in reducing 
liver or spleen weight following concanavalin A insult.  Interestingly, although there is no 
significant effect on muscle wasting in this model, activin B antibody treatment significantly 
increased muscle mass after only approximately 28 hours. 
 
Figure 3-10 H&E staining in liver following activin antibody treatment and intravenous 
concanavalin A administration.  Lean male Balb/c mice were administered antibody treatment 
listed and a single dose of concanavalin A intravenously 16 hours later.  Liver sections were 
subjected to hematoxylin and eosin staining.  Representative images of (A) PBS treated, (B) IgG 
+ ConA, (C) anti-activin A + ConA, and (D) anti-activin B + ConA treatment are presented here. 
 
Hematoxylin and eosin staining was performed on liver sections following study termination; 
concanavalin A treatment resulted in widespread necrotic damage to hepatocytes and cell death.  
In animals treated with either activin A or B antibody, this resulting damage to hepatocytes 
following concanavalin A administration was almost completely absent.  This protective effect 
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on hepatocytes following inhibition of activin A or B is reflected by lowering of serum ALT and 
AST levels as well.      
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Figure 3-11 Response of ALT and AST following activin antibody treatment and 
intravenous concanavalin A administration. Lean male Balb/c mice were administered a single 
dose of antibody treatment listed and a single dose of concanavalin A intravenously 16 hours later.  
Serum levels of ALT (A) and AST (B) were measured from serum collected 12 hours post-dose.  
Data are expressed as mean ± S.E.M. (n=8 mice/group). Significance is indicated *P ≤ 0.05, treated 
group versus IgG control group (Dunnett’s one-way ANOVA).   
 
Both activin A and B antibodies, when administered prophylactically prior to concanavalin A 
administration, showed significant reductions in ALT and AST in serum suggesting a protective 
effect of hepatocytes against injury induced by immune activation in the liver. 
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Figure 3-12 Response of bilirubin and bile acids following activin antibody treatment and 
intravenous concanavalin A administration. Lean male Balb/c mice were administered a 
single dose of antibody treatment listed and a single dose of concanavalin A intravenously 16 
hours later.  Serum levels of bilirubin (A) and bile acids (B) were measured from serum collected 
12 hours post-dose.  Data are expressed as mean ± S.E.M. (n=8 mice/group). Significance is 
indicated *P ≤ 0.05, **P ≤ 0.01 treated group versus IgG control group (Dunnett’s one-way 
ANOVA).   
 
Activin A and B antibodies also showed significant effects in lowering total bilirubin and 
reduction of total bile acids. 
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Figure 3-13 Response of glucose and cholesterol following activin antibody treatment and 
intravenous concanavalin A administration. Lean male Balb/c mice were administered a 
single dose of antibody treatment listed and a single dose of concanavalin A intravenously 16 
hours later.  Serum levels of glucose (A) and cholesterol (B) were measured from serum 
collected 12 hours post-dose.  Data are expressed as mean ± S.E.M. (n=8 mice/group). 
Significance is indicated *P ≤ 0.05, **P ≤ 0.01 treated group versus IgG control group 
(Dunnett’s one-way ANOVA).   
 
Both antibody treatments showed a modest protection of gluconeogenesis (although not 
significant) following concanavalin A administration, and no effect on total cholesterol (although 
total cholesterol in this particular model does not seem to be affected). 
Neutralization of both activin A and B conferred protective effects against immune-mediated 
liver injury induced by concanavalin A administration (reflected by significant reduction in 
serum ALT, AST, and bilirubin).  To investigate mechanistically how neutralization of activin A 
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and B might confer these benefits, we analyzed IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-
12p70, KC/GRO, and TNFα in terminal serum samples.  Inhibition of activin A and B resulted in 
significant decreases in TNFα, IL-2, and IL-4. 
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Figure 3-14 TNFα in serum following activin antibody treatment and intravenous 
concanavalin A administration. Lean male Balb/c mice were administered a single dose of 
antibody treatment listed and a single dose of concanavalin A intravenously 16 hours later.  
Serum levels of TNFα were measured via Meso Scale Discovery Electrochemiluminescence 
from serum collected 12 hours post-dose.  Data are expressed as mean ± S.E.M. (n=8 
mice/group). Significance is indicated *P ≤ 0.05, ****P ≤ 0.001 treated group versus IgG control 
group (Dunnett’s one-way ANOVA). 
 
Both activin A and B antibodies significantly reduced circulating levels of TNFα following 
concanavalin A administration.  TNFα is a pleiotropic cytokine, produced by multiple immune 
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cell types including macrophages and monocytes and triggers multiple pathways involved in 
proliferation, inflammation, and apoptosis 53.  One major source of TNFα is phagocytosis of 
apoptotic hepatocytes by HSCs and Kupffer cells, leading to upregulation of TNFα and 
additional profibrogenic factors 54.  In regards to fibrosis, TNFα has been shown to induce 
proinflammatory and immunogenic activity in dendritic cell in the liver 55, and blocking TNFα 
has been shown to inhibit HSC activation by C-C motif chemokine receptor (CCR) 9+ 
macrophages 56.  It stands to reason that TNFα is an essential factor in the initialization and 
progression of liver fibrosis.  Inhibition of activins in this case may reduce circulating levels of 
TNFα by prevention of hepatocyte death (as measured by ALT and AST), preventing TNFα 
production by HSCs and Kupffer cells engulfing apoptotic hepatocytes.  How exactly activins 
may be involved in hepatocyte preservation in this disease model needs to further investigated. 
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Figure 3-15 IL-2 in serum following activin antibody treatment and intravenous 
concanavalin A administration. Lean male Balb/c mice were administered a single dose of 
antibody treatment listed and a single dose of concanavalin A intravenously 16 hours later.  
Serum levels of IL-2 were measured via Meso Scale Discovery Electrochemiluminescence from 
serum collected 12 hours post-dose.  Data are expressed as mean ± S.E.M. (n=8 mice/group). 
Significance is indicated *P ≤ 0.05, treated group versus IgG control group (Dunnett’s one-way 
ANOVA). BQL - below quantifiable limit. 
 
Neutralization of activin B showed significant reduction of circulating IL-2, and neutralization of 
activin A reduced IL-2 to a lesser effect.  IL-2 is primarily derived from activated CD4+ T cells, 
48 
 
 
activated CD8+ T cells, NK cells, dendritic cells and macrophages 57.  IL-2 plays a number of 
roles in immune regulation, many of which have implications regarding chronic injury and 
fibrosis, including: promoting T-cell differentiation to effector or memory cells when the T-cell 
is stimulated by antigen 57, development of proliferation-competent memory cells, priming of 
CD8+ cells with non-infectious immunogens, and maintenance of T-cells during chronic 
infection 58.  Reduction of IL-2 in this model is likely due to suppression of activation of T-cells 
and macrophages from concanavalin A stimulation.   
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Figure 3-16 IL-4 in serum following activin antibody treatment and intravenous 
concanavalin A administration. Lean male Balb/c mice were administered a single dose of 
antibody treatment listed and a single dose of concanavalin A intravenously 16 hours later.  
Serum levels of IL-4 were measured via Meso Scale Discovery Electrochemiluminescence from 
serum collected 12 hours post-dose.  Data are expressed as mean ± S.E.M. (n=8 mice/group). 
Significance is indicated *P ≤ 0.05, treated group versus IgG control group (Dunnett’s one-way 
ANOVA). BQL - below quantifiable limit. 
 
Both activin A and B neutralization resulted in significant lowering of IL-4 in circulation.  IL-4 
promotes alternative activation of resident macrophages in the liver into M2 macrophages, and 
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depending on context, M2 macrophages may exhibit pro or anti-fibrotic activity 59.  In vivo, IL-
4/IL-13 double knockout animals (both of which bind IL-4Rα) showed resistance to 
development of fibrosis induced by CCL4 administration, but deletion of  IL-4Rα spontaneous 
fibrosis reversal is inhibited 59.  In this context, it is more likely that inhibition of IL-4 would be 
desirable to prevent development of fibrosis.  
3.3 Antibody neutralization of activin A and B in CCl4-induced liver fibrosis 
We demonstrated that neutralization of activin A and B showed protective effects in an acute 
model of immune-mediated liver injury and showed potential for anti-fibrotic activity.  We next 
sought to determine whether neutralization of activins could have the potential to reverse 
established fibrosis in a CCL4-induced model of liver fibrosis.  Mice were randomized by body 
weight (n=8) and administered corn oil or CCL4.  CCL4 was injected twice weekly for 10 weeks; 
on the seventh week after the establishment of fibrosis, we began weekly administration of the 
following treatments: 
Table 3-3 Groups in CCl4 activin A and B neutralization study 
Group Number Treatment Stimulation 
1 PBS (10 mL/kg, SC) Corn oil (10 mL/kg, IP) 
2 mIgG1 (60 mg/kg, SC) CCl4 (1 mL/kg, IP) 
3 
Anti-Activin A  
(10 mg/kg, SC) 
CCl4 (1 mL/kg, IP) 
4 
Anti-Activin B  
(50 mg/kg, SC) 
CCl4 (1 mL/kg, IP) 
5 
Anti-A (10 mg/kg, SC) 
+  
Anti-B (50 mg/kg, SC) 
CCl4 (1 mL/kg, IP) 
6 
AcvRIIB Fc 
(10 mg/kg, SC) 
CCl4 (1 mL/kg, IP) 
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In this study, we included two extra groups: combination treatment of both activin A and B 
antibody, and pan inhibitor soluble decoy receptor AcvRIIB as a positive control.  The 
combination group was included to test if neutralization of both ligands may have additive or 
synergistic effects in a fibrosis model. 
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Figure 3-17 Lean mass % change from baseline following activin antibody treatment in 
CCl4-induced hepatic fibrosis. Lean female C57bl/6 mice were administered weekly treatment 
listed after establishment of fibrosis.  Weekly body composition was evaluated via qNMR, and 
lean mass reported as percent change from study baseline.  Data are expressed as mean ± S.E.M. 
(n=8 mice/group).  
 
Throughout the course of the study, body composition was monitored via qNMR.  Muscle 
wasting is a common comorbidity associated with clinical hepatic fibrosis and end-stage liver 
disease, and incidence has been shown to progress with disease 60.  In our study, neutralization of 
activin A and B both had protective benefits to maintaining lean mass during progression of the 
disease.  Combination treatment with both neutralizing antibodies had an enhanced effect and 
actually increased lean mass compared to baseline, suggesting neutralization of activin A and B 
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may confer this preservation of lean mass through different mechanisms or may modulate the 
activity of one another. 
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Figure 3-18 Tissue wet weights following activin antibody treatment in CCl4-induced 
hepatic fibrosis.  Lean female C57bl/6 mice were administered weekly treatment listed after 
establishment of fibrosis.  Wet tissue weights of gastrocnemius (A) and liver (B) were measured at 
study termination.  Data are expressed as mean ± S.E.M. (n=8 mice/group).  Significance is indicated 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005, ****P ≤ 0.001, treated group versus IgG control group 
(Dunnett’s one-way ANOVA). 
 
At study termination, wet tissue weights of liver and gastrocnemius were taken.  Neutralization 
of both activin A and B had the same magnitude of effect in maintaining liver weight, and 
combination of neutralizing both had an additive effect.  Neutralization of activin A, but not 
activin B, maintained gastrocnemius weight; both combo neutralization and soluble receptor 
treatments had similar effect to activin A neutralization alone. 
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Figure 3-19 ALT and AST following activin antibody treatment in CCl4-induced hepatic 
fibrosis.  Lean female C57bl/6 mice were administered weekly treatment listed after 
establishment of fibrosis.  Serum levels of ALT (A) and AST (B) were measured from serum 
collected at study termination.  Data are expressed as mean ± S.E.M. (n=8 mice/group).  Significance 
is indicated *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005, ****P ≤ 0.001, treated group versus IgG control 
group (Dunnett’s one-way ANOVA). 
 
Both activin A and B neutralization showed benefits in reducing serum ALT and AST after 
establishment of fibrosis, and the severity of the liver injury at this point is quite apparent due to 
the massive increase in ALT and AST in circulation compared to corn oil treated controls.  
Additionally, neutralization of both activins resulted in a marked decrease in both ALT and AST 
compared to either treatment alone.  
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Figure 3-20 Bilirubin and bile acids following activin antibody treatment in CCl4-induced 
hepatic fibrosis.  Lean female C57bl/6 mice were administered weekly treatment listed after 
establishment of fibrosis.  Serum levels of bilirubin (A) and bile acids (B) were measured from 
serum collected at study termination.  Data are expressed as mean ± S.E.M. (n=8 mice/group).  
Significance is indicated *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005, ****P ≤ 0.001, treated group versus 
IgG control group (Dunnett’s one-way ANOVA). 
 
Neither neutralization of activin A nor B alone significantly reduced bilirubin, but when 
neutralized in combination a significant lowering was seen compared to control.  Neutralization 
of A and B separately (B more so than A) significantly lowered bile acids.  Neutralization of 
both ligands slightly improved this reduction. 
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Figure 3-21 Glucose and cholesterol following activin antibody treatment in CCl4-induced 
hepatic fibrosis.  Lean female C57bl/6 mice were administered weekly treatment listed after 
establishment of fibrosis.  Serum levels of glucose (A) and cholesterol (B) were measured from 
serum collected at study termination.  Data are expressed as mean ± S.E.M. (n=8 mice/group).  
Significance is indicated *P ≤ 0.05, ***P ≤ 0.005, ****P ≤ 0.001, treated group versus IgG 
control group (Dunnett’s one-way ANOVA). 
 
Glucose levels were not significantly improved by neutralization of either activin A or B alone, 
but combination neutralization of both ligands resulted in a highly significant improvement.  
Likewise, neutralizing either ligand alone showed no improvement in cholesterol in serum, but 
combination neutralization significantly reduced cholesterol to levels below corn oil control. 
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Figure 3-22 MTS staining in liver following activin antibody treatment in CCl4-induced 
hepatic fibrosis.  Lean female C57bl/6 mice were administered weekly treatment listed after 
establishment of fibrosis.  Liver sections were subjected to Masson's trichrome staining and (A) 
% positive area staining for collagen was quantified using ImageJ.  Representative images of (B) 
corn oil, (C) IgG, (D) anti-activin A, (E) anti-activin B, (F) antibody combination, and (G) 
AcvRIIB Fc treatment are presented here.  Data are expressed as mean ± S.E.M. (n=8 
mice/group).  Significance is indicated **P ≤ 0.01, ****P ≤ 0.001, treated group versus IgG 
control group (Dunnett’s one-way ANOVA). 
 
A main endpoint of this study was to perform Masson’s trichrome staining on liver sections in 
order to visualize and quantitate collagen deposition and fibrosis following CCl4 administration 
and demonstrate if inhibition of either activin may reverse disease progression.  The results from 
10 weeks of CCl4 administration are quite striking – nearly 20% of the liver of IgG treated 
animals is fibrotic.  This fibrosis is prevalent throughout the entire liver, and is not contained to 
only areas surrounding vasculature.  Even more surprising is the marked effect neutralization of 
activin A and B has in reducing fibrosis in this model.  Both A, and to greater effect B, 
significantly reduce fibrosis; there does not seem to be increased effect when both ligands are 
neutralized. 
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Figure 3-23 F4/80 staining in liver following activin antibody treatment in CCl4-induced 
hepatic fibrosis.  Lean female C57bl/6 mice were administered weekly treatment listed after 
establishment of fibrosis.  Liver sections were stained with anti-F4/80 and (A) % positive area 
staining was quantified using ImageJ.  Representative images of (B) corn oil, (C) IgG, (D) anti-
activin A, (E) anti-activin B, (F) antibody combination, and (G) AcvRIIB Fc treatment are presented 
here.  Data are expressed as mean ± S.E.M. (n=8 mice/group).  Significance is indicated **P ≤ 0.01, 
***P ≤ 0.005, ****P ≤ 0.001, treated group versus IgG control group (Dunnett’s one-way 
ANOVA). 
 
Immunostaining of liver sections with anti-F4/80 was also performed and quantitated - F4/80 is a 
marker of murine macrophages and Kupffer cells.  CCl4 administration significantly increased 
macrophage infiltration into the liver compared to corn oil treated mice.  Neutralization of 
activin A, B, and the combination all were effective in significantly reducing macrophage 
numbers to near baseline levels.  There did not seem to be any sort of additive or synergistic 
effects in combination neutralization of both ligands.  
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Figure 3-24 Ki67 staining in liver following activin antibody treatment in CCl4-induced 
hepatic fibrosis.  Lean female C57bl/6 mice were administered weekly treatment listed after 
establishment of fibrosis.  Liver sections were stained with anti-Ki67 and (A) % positive cells 
stained was quantified using ImageJ.  Representative images of (B) corn oil, (C) IgG, (D) anti-activin 
A, (E) anti-activin B, (F) antibody combination, and (G) AcvRIIB Fc treatment are presented here.  
Data are expressed as mean ± S.E.M. (n=8 mice/group).  Significance is indicated *P ≤ 0.05, **P ≤ 
0.01, ****P ≤ 0.001, treated group versus IgG control group (Dunnett’s one-way ANOVA). 
 
Proliferative action in the liver was quantified by Ki67 staining.  In the context of liver, increase 
in proliferation is largely reflective hepatocytes re-entering the cell cycle from quiescence 
following damage 61.  This increase in proliferation may also be reflective of the activation of 
HSCs into proliferative, pro-fibrogenic myofibroblast-like cells.  CCl4 administration resulted in 
significant positive staining of Ki67 compared to corn oil treatment, suggesting widespread 
damage and apoptosis in hepatocytes and activation of HSCs.  Neutralization of activin B, but 
not activin A, significantly reduced this proliferation seen with CCl4 administration; 
neutralization of both antibodies in combination did not improve effect compared to B 
neutralization alone. 
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Figure 3-25 MPO staining in liver following activin antibody treatment in CCl4-induced 
hepatic fibrosis.  Lean female C57bl/6 mice were administered weekly treatment listed after 
establishment of fibrosis.  Liver sections were stained with anti-MPO and (A) % positive area 
staining was quantified using ImageJ.  Representative images of (B) corn oil, (C) IgG, (D) anti-
activin A, (E) anti-activin B, (F) antibody combination, and (G) AcvRIIB Fc treatment are presented 
here.  Data are expressed as mean ± S.E.M. (n=8 mice/group).  Significance is indicated *P ≤ 0.05, 
**P ≤ 0.01, ****P ≤ 0.001, treated group versus IgG control group (Dunnett’s one-way 
ANOVA). 
 
Myeloperoxidase (MPO) is a peroxidase enzyme abundantly expressed in neutrophil 
granulocytes – in normal and acutely damaged rat liver, MPO expression is only found in 
neutrophil granulocytes, but not in macrophages 62.  CCl4 administration significantly increased 
neutrophil infiltration into liver compared to corn oil treated animals, but neither activin A, 
activin B, or the neutralization of both showed any effects on neutrophils in the liver.     
Neutralization of activin A and B individually both showed significant improvements in 
parameters of liver damage, liver function, fibrosis, and macrophage infiltration in a CCl4-
induced model of liver fibrosis after establishment of disease.  Activin B neutralization showed a 
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more robust effect in reducing fibrosis and also significantly reduced hepatocyte and HSC 
proliferation which activin A neutralization did not.  Combination neutralization of both ligands 
showed additive or synergistic effects in certain parameters, including protection of hepatocytes 
(via reduced ALT and AST), gluconeogenesis, cholesterol metabolism, bilirubin and bile acid 
production, and preservation of lean mass.  Overall, neutralization of activin A, B, and the 
combination of both showed profound benefits in this experimental model of liver fibrosis.  
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CHAPTER 4. DISCUSSION 
 
4.1 Characterization of concanavalin A induced immune hepatitis 
Tissue injury and the resulting inflammatory response acts as an important trigger for the 
initiation of regenerative processes and the development of fibrosis; in many diseases this 
inflammatory response is essential for fibrosis to occur at all 63.  Understanding how activins are 
modulated during this initial inflammatory response may provide insights as to if and how they 
may affect the initiation and progression of liver fibrosis.  Concanavalin A-induced hepatitis 
provides a convenient, short-term model of inflammation highly specific to the liver mediated 
through activation of T-cells and macrophages.  Concanavalin A may also have direct 
stimulatory effects on resident HSCs, a major cellular contributor to the initiation and 
progression of fibrosis.  HSCs directly stimulated by concanavalin A have been shown to induce 
oxidative stress and apoptosis of hepatocytes in the absence of other effector cell types 64.  In our 
hands, concanavalin A administration resulted in trademarks of severe, acute inflammatory 
response in the liver – increases in enzymes reflective of hepatocyte death (ALT and AST), and 
impaired function (serum bilirubin and glucose).  We demonstrated how activins are modulated 
during this acute phase inflammation – circulating activin B levels were massively increased, 
nearly 20 fold compared to control animals.  It is clear that activin B production is to a certain 
extent hepatically derived, as reflected by a roughly 50-fold increase in inhibin B expression and 
significant increase in liver-specific protein.  However, this substantial increase in circulating 
activin B was even observed in dosages of concanavalin A where there were no measureable 
effects on clinical parameters of liver injury or function.  This finding is suggestive of some 
subpopulation of activated immune cells potentially being an alternative source of activin B 
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production during the inflammatory phase.  To further support this notion we also observed 
significant increases in inhibin B expression and activin B protein in the spleen.  Measurement of 
activin B by ELISA in the conditioned cell media of stimulated splenocytes would be a simple 
method of ascertaining whether or not some leukeocyte may be responsible for production of 
activin B.  Regarding activin A, we saw only slight effects in circulating protein 12 hours 
following stimulation of concanavalin A.  As previously mentioned, in a model of LPS-induced 
liver inflammation, activin A production was significantly increased immediately following 
stimulation, but dropped rapidly 3 hours following stimulation 48.  In the content of the 
concanavalin A model, is very likely that production of activin A by inflammatory insult is very 
rapid and transient, and 12 hours following initial stimulation levels have already decreased 
substantially.  This notion is further supported by the fact that we observe significant 
downregulation of activin A in the liver at 12 hours post-stimulation, likely due to inhibitory 
feedback from initial signaling.  Ideally, it would be best to perform characterization of this 
model throughout the entire time course of stimulation, from the initial inflammatory response 
all the way to resolution.  Regardless, our characterization of this model demonstrated the 
modulation of activins in the context of acute liver inflammation, and therefore how activins 
might be involved in the pathology of fibrosis. 
4.2 Antibody neutralization of activin A and B in concanavalin A-induced immune 
hepatitis 
Neutralization of activin A and B conferred pronounced effects in our concanavalin A immune-
mediated hepatitis model – blocking either A or B protected hepatocytes and significantly 
lowered ALT and AST in the serum at 12 hours post-stimulation, and improved liver function 
(significantly decreased serum bilirubin).  We saw significant reductions in serum cytokines 
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TNFα, IL-2, and IL-4 when neutralizing activin A or B prior to concanavalin A stimulation.  
TNFα is a known promoter of liver fibrosis;  inflammation in the liver is perpetuated by TNFα 
production, which results in the activation of resident HSCs into fibrogenic myofibroblasts 53.  
TNFα has also been shown to directly induce apoptosis in hepatocytes 65.  Mechanistically, it is 
uncertain how exactly activin neutralization is modulating TNFα in this model.  Phagocytosis of 
apoptotic hepatocytes by HSCs or macrophages upregulates TNFα, and chronic activation of 
these cells accelerates hepatocyte apoptosis and inflammation, leading to a positive feedback 
loop 54.  Activin neutralization may inhibit activation or recruitment of macrophages during acute 
inflammation, blunting the upregulation of TNFα from phagocytosis of apoptotic hepatocytes.  
Activin neutralization may also inhibit the activity of concanavalin A to stimulate activation of 
HSCs.  Examining histological markers of macrophages and proliferation might provide clues as 
to how exactly activin neutralization downregulates TNFα.  IL-2 is a Th1 cytokine, responsible 
for macrophage activation among other functions 66.  This downregulation of IL-2 may provide 
an explanation as for the downregulation of TNFα we observed, as macrophage activation may 
be inhibited.  The main source of IL-2 in this model is likely from activated T-cells; activins may 
play a role in the activation or proliferation of T-cells following stimulation.  It may be beneficial 
to explore this relationship by characterizing isolated CD3+ cells and subpopulations after 
treatment with exogenous activins.  IL-4 is a Th2 cytokine, responsible for induction of naïve T-
helper cells to Th2 cells – it also promotes alternative polarization of macrophages to M2 
macrophages and inhibits M1 polarization.  Acutely, M2 macrophages promote controlled 
wound healing and tissue regeneration though IL-10, TGFβ, and other secreted factors 67.  When 
chronically activated, however, M2 macrophages can activate resident fibroblasts and promote 
fibrosis 68; downregulation of IL-4 in chronic liver injury may confer anti-fibrotic effects and 
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inhibit the progression of fibrogenesis.  Overall, neutralization of activins confers benefits during 
acute-phase inflammation, and may confer benefits during chronic inflammation and 
fibrogenesis. 
4.3 Antibody neutralization of activin A and B in carbon tetrachloride-induced liver 
fibrosis 
We characterized activins in the context of the acute inflammatory phase, demonstrated 
protective effects in the liver via inhibition of activins following immune stimulation, and 
provided some insight mechanistically as to how activin inhibition may be conferring these 
benefits and how activin modulation may be involved in chronic inflammation and the initiation 
and progression of fibrosis.  The final step was to characterize the effects of activin 
neutralization in an experimental model of liver fibrosis.  CCl4 is a commonly used, highly 
potent, and well-characterized hepatotoxin used in preclinical rodent models to induce liver 
fibrosis; CCl4 increases lipid profile, liver enzymes, and oxidative stress markers, while 
decreasing total protein and high-density lipoprotein 69.  More importantly, histological changes 
in inflammation, loss of normal hepatocytes, collagen deposition and fiber segmentation 
formation are observed following CCl4 administration 
70.  This collagen deposition and ECM 
formation is driven by recruitment and activation of HSCs to the site of tissue injury, which 
transdifferentiate into myofibroblast-like cells, driven by increased TGFβ signaling 71.  In our 
experiment, we opted to allow for development of disease by administering CCl4 without therapy 
for six weeks, to evaluate the effect of activin neutralization in a therapeutic modality versus 
preventative.  We observed striking results following CCl4 administration for 10 weeks: a 
massive increase in liver damage enzymes, marked decreases in parameters of liver function, 
severe impact on gluconeogenesis, profound infiltration of macrophages, proliferation of 
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hepatocytes and HSCs, pervasive collagen deposition, and collection and retention of ascetic 
fluid in the abdomen.  CCl4 administration over a 10-week period is representative of clinical 
presentation of advanced liver disease with concurrent fibrosis.  Regardless of the severity of the 
model, neutralization of activins showed drastic effects in resolving complications from 
inflammatory insult and fibrogenesis resulting from CCl4 administration.  We saw improvements 
in liver function, protection from liver damage, resolution of fibrosis, and reduction in 
macrophage infiltration.  The reduction we see in chronic recruitment and activation of 
macrophages may be explained by the reduction of TNFα we saw during the acute inflammatory 
phase when inhibiting activins.  Reduced circulating IL-2 and IL-4 we observed during acute 
inflammation following activin neutralization would reflect decreased polarization of 
macrophages towards M1 and M2 states during chronic injury, respectively, modulating the 
acute pro-inflammatory response (M1) throughout disease progression as well as fibrotic 
responses, ECM deposition, and fibroblast activation (M2).  Additionally, we observed some 
differentiation between activin A and B neutralization in this model.  Activin B inhibition 
resulted in a significant reduction in proliferation, and overall had better effects in resolving 
fibrosis than activin A inhibition.  Mechanistically, activin B is involved in the activation and 
proliferation of HSCs and proliferation of hepatocytes following apoptosis either directly or 
indirectly (as indicated by significant effects on proliferation), which also explains the enhanced 
reduction in fibrosis versus activin A inhibition alone.  It is worth exploring this distinction of 
activin B from A, by characterizing the stimulatory response of isolated hepatocytes or HSCs to 
exogenous activin A or B treatment.  Finally, we observed some additive or synergistic effects 
when both activin A and B were neutralized in this model.  Combination therapy improved 
protection of hepatocytes (via reduced ALT and AST), gluconeogenesis, cholesterol metabolism, 
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liver function, and preservation of lean mass; these improvements in combination therapy versus 
individual inhibition of either ligand alone suggests activin A and B may be operating through 
different pathways to confer similar effects, or that the two ligands may modulate the activities 
of one another.  These observations warrant further investigation into the dynamics of actin A 
and B signaling in relation to one another, in particular regard to muscle metabolism which was 
unfortunately beyond the scope of the work performed here.  Overall, neutralization of either or 
both ligands showed promising liver protective and anti-fibrotic activity in our pre-clinical model 
of liver fibrosis. 
4.4 Conclusions     
Tissue injury and the resulting acute inflammatory response is an essential stimuli for the 
initiation and progression of fibrosis encountered during chronic liver disease.  Using an 
immune-mediated model of acute liver inflammation, we were able to characterize resulting liver 
damage and impairments to liver function following insult and how activin A and B are 
modulated during this initial response.  We provided mechanistic insights into activin A and B 
activity in the context of acute inflammation by neutralization via antibody in our concanavalin 
A model, and demonstrated the protective effects of inhibition of these ligands.  Finally, we 
showed how activin A and B neutralization inhibited liver injury, improved liver function, and 
reduced fibrosis in a chronic model of CCl4-induced liver fibrosis and explored mechanistically 
how neutralizing activins conferred these benefits.  Our data taken together suggest activin A and 
B as important players during not only initial inflammatory response, but also during chronic, 
sustained inflammation and fibrogenesis in the liver and show the therapeutic potential of 
targeting of these ligands in chronic liver disease and fibrosis. 
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